Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share
Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.
The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS2ion’s planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture partner AdaptVac ApS.
The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden’s website: https://www.aktiespararna.se/analysguiden/Hitta-Bolag/health-care/expres2ion-biotech-holding/analys.
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
Brighter AB (publ) Year-end report 2020
Operating result for the period amounted to SEK -101,604 thousand (-35,029). Brighter contributed SEK -81,472 thousand to the operating result and the rest refers to Camanio and Pink Nectarine Health which were acquired in Q4 2019 and Q1 2020. Among the reasons for the higher loss were additions of...
First Non-Cancer Scalp Cooling Study for the Prevention of Chemotherapy-induced Hair Loss in Pediatric Patients
An observational, prospective pilot study will see the use of a Paxman Scalp Cooling System for the first time in such research.The research “Pilot Study of Cold Cap Therapy for Prevention of Hair loss in Pediatric Patients Receiving Chemotherapy for Non-Malignant Indications” is not only the first...
Första skalpkylningsstudien med icke-cancerpatienter för att motverka cellgiftsinducerat håravfall hos barn och unga
En pilotstudie i form av en prospektiv observationsstudie kommer att utgöra första gången som Paxman Scalp Cooling System används inom det här forskningsområdet.Utöver att vara den första studien då Paxmans skalpkylningssystem används av en patientgrupp som består av barn och unga så är studien “Pil...
Announcement from FRISQ's annual general meeting
Adoption of the income statement and the balance sheetThe AGM resolved to adopt the income statement and the balance sheet in FRISQ and the consolidated income statement and the consolidated balance sheet.Allocation of profitThe AGM resolved that no dividend would be paid to the shareholders and tha...